Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Akeso: Clinical Trials & FDA Approval Profile

Akeso (Global / Institutional) sponsors 123 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 67 active protocols (32 recruiting now), 46 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.5%
Median Closed Enrollment vs National (145 pts)112 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Akeso
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)123
Active Pipeline (Recruiting Now)67 (32)
Completed vs Stopped Early46 / 8 (6.5%)
Median Closed Actual Enrollment112 participants
Physical Hospital Site Disclosure87.4% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Akeso
Hospital Research SiteLocationShared Protocols
Zhejiang Cancer HospitalHangzhou, Zhejiang12
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality10
Hunan Cancer HospitalChangsha, Hunan9

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Akeso
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06196203A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic SyndromesPhase IIRECRUITING
NCT07010263A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following ConcurrPhase IIIRECRUITING
NCT07700979Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of ParPhase IIIRECRUITING
NCT05859750A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic CancerPhase IIRECRUITING
NCT05235516A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical CancerPhase IIIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Akeso Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI